Boston Scientific Corporation (BSX)
Boston Scientific is a global medical technology company that designs and manufactures devices used in minimally invasive medical procedures.
Is Boston Scientific Corporation a good stock for a UK beginner?
The honest version: Boston Scientific is a global medical technology company that designs and manufactures devices used in minimally invasive medical procedures.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Dominance in high-growth minimally invasive surgery markets.
Major technological shifts making current product lines obsolete.
What does Boston Scientific Corporation do?
The company creates tools for doctors to perform surgeries through tiny incisions, focusing on areas like heart health, digestive issues, and pain management. Selling these specialised medical devices to hospitals and clinics worldwide is what generates its earnings. Their momentum hinges on continually innovating and securing regulatory approval for new medical tools in a competitive healthcare market.
On our factor screen it looks strongest on quality and value, and weakest on momentum.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 8% over the year
- ✓Very profitable - turns about 17% of sales into profit
- Quality screens high (72/100)
- High gross margins suggest strong demand for their specialised products.
- Operates in a sector with steady, long-term demand from an ageing population.
- Lower beta indicates the stock may be less sensitive to broad market swings.
- Momentum screens low (11/100)
- Income screens low (16/100)
- Potential for product recalls or legal issues related to medical devices.
- Changes in government healthcare policy affecting how hospitals are funded.
- Intense competition from other large medical technology firms.
What do Boston Scientific Corporation's numbers mean?
How much money does Boston Scientific Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Boston Scientific Corporation pay a dividend?
No - Boston Scientific Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Boston Scientific Corporation report earnings, and how did recent quarters go?
Boston Scientific Corporation is next scheduled to report on about 2026-10-21 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-29 | $0.83 | $0.86 | Beat +4% |
| 2026-04-22 | $0.79 | $0.80 | Beat +2% |
| 2026-02-04 | $0.78 | $0.80 | Beat +2% |
| 2025-10-22 | $0.71 | $0.75 | Beat +5% |
| 2025-07-23 | $0.73 | $0.75 | Beat +3% |
| 2025-04-23 | $0.67 | $0.75 | Beat +12% |
Across the last 6 quarters here, Boston Scientific Corporation came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Boston Scientific Corporation?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Boston Scientific Corporation?
How many points the write-up makes each way — a balance check, not a score or verdict.
- High gross margins suggest strong demand for their specialised products.
- Operates in a sector with steady, long-term demand from an ageing population.
- Lower beta indicates the stock may be less sensitive to broad market swings.
- Does not pay a dividend, which may not suit those looking for regular income.
- High reliance on constant innovation to stay ahead of competitors.
- Subject to strict and often unpredictable government healthcare regulations.
- Potential for product recalls or legal issues related to medical devices.
- Changes in government healthcare policy affecting how hospitals are funded.
- Intense competition from other large medical technology firms.
The write-up's own warning lights — if these start happening, the case above changes.
- A significant, sustained drop in gross margins would suggest pricing power is fading.
- A major regulatory failure that prevents key products from reaching the market.
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.